Eptinezumab as an Adjunct to Standard of Care for Migraine in an Acute Emergency Context

Launched by DR GEORGE MEDVEDEV · May 22, 2024

Keywords

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Adults between the ages of 19-75 with a history of migraines, as established at the time of presentation to the ED or known from the patient's chart;
• • 2. Presenting to the emergency department with a migraine that meets ICHD-3 migraine headache criteria;
• • 3. Provided signed informed consent;
• • 4. Sufficient literacy and cognitive capacity to understand and complete patient self-rated questionnaires in English.
• Exclusion Criteria:
• • 1. Secondary headaches caused by an injury or underlying illness, such as a concussion, bleeding in the brain, an infection or a brain tumor
• • 2. Current or history of severe cardiovascular disease or renal dysfunction
• • 3. A systemic condition in the stage of active treatment (vasculitis, etc.)
• • 4. Pregnant or at risk of becoming pregnant (absent contraception)
• • 5. Currently enrolled in another investigational drug trial
• • 6. Dosed with eptinezumab within the past 3 months
• • 7. Currently on anti-CGRP therapy with monoclonal antibodies
• • 8. Currently involved in active litigation
• • 9. Any other condition which, in the opinion of the Investigator, would exclude the participant due to reasons of safety or data integrity
• • 10. Hypersensitivity to the active substance or to any of the excipients